Biogen Stock News

TOKYO and CAMBRIDGE, Mass. , Dec. 23, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , ", Biogen", )) announced today that lecanemab, an investigational anti-amyloid beta (A) protofibril antibody for the treatment of early Alzheimer''s disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab in June of 2021. Breakthrough Therapy designation and Fast Track designation are two FDA programs that are intended to facilitate and expedite development of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition such as AD and provide opportunities for frequent interactions with the FDA.. In September 2021 , Eisai initiated a rolling submission to the FDA of a Biologics License application (BLA) for lecanemab under the accelerated approval pathway.

Biogen: All About Aduhelm Again In 2022, But Expecting Upside

Biogen (NASDAQ:BIIB) had its target price reduced by equities research analysts at Bank of America from $295.00 to $275.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a neutral rating on the biotechnology companys stock. Bank of Americas price target indicates a potential upside of 17.28% from the companys previous []

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at William Blair lifted their Q4 2021 EPS estimates for Biogen in a research note issued to investors on Monday, December 20th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings of $3.56 per share for the quarter, up from their prior forecast of […]

Can Biogen pull itself back from the brink in 2022?

Biogen (NASDAQ:BIIB) had its price objective dropped by equities research analysts at Robert W. Baird from $296.00 to $258.00 in a research note issued to investors on Tuesday, Price Targets.com reports. The firm currently has a neutral rating on the biotechnology companys stock. Robert W. Bairds price target would indicate a potential upside of 10.03% [] The post Robert W. Baird Lowers Biogen (NASDAQ:BIIB) Price Target to $258.00 appeared first on ETF Daily News .

Biogen Inc. (BIIB) closed the most recent trading day at $234.48, moving -0.07% from the previous trading session.

Biogen has been one of the biggest U.S. blue-chip losers since June, mostly on troubles launching its first-to-market Alzheimer's drug.

CAMBRIDGE, Mass., Dec. 22, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation C

Save(0) Please login to bookmark Username or Email Address Password Remember Me Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to [] Subscribe for instant access to all Lawyerly content. Already a subscriber? Username or Email Address Password Remember Me Lost your password? Want to test drive Lawyerly? Contact us to take a free trial. The post Biogen wins discovery for potential IP lawsuit against Sandoz appeared first on Lawyerly .